EFFICACY OF VARIOUS DRUG FORMS OF LYCOPENE IN PATIENTS WITH DYSLIPIDEMIA

Aim. To find the optimal scheme of lycopene application and to compare clinical efficacy of two lycopene presentations produced on the basis of 1) vegetable oil and 2) milk protein (lactolycopene) in patients with dyslipidemia.Material and methods. At the first step of the study to choice an optimal...

Full description

Bibliographic Details
Main Authors: P. Ya. Dovgalevsky, V. A. Klochkov, N. E. Chalyk, O. M. Ansimova, I. Petyaev
Format: Article
Language:English
Published: Stolichnaya Izdatelskaya Kompaniya 2016-01-01
Series:Racionalʹnaâ Farmakoterapiâ v Kardiologii
Subjects:
Online Access:https://www.rpcardio.com/jour/article/view/844
id doaj-7e22936367b04eb1a96684a9483f3324
record_format Article
spelling doaj-7e22936367b04eb1a96684a9483f33242021-09-03T13:15:20ZengStolichnaya Izdatelskaya KompaniyaRacionalʹnaâ Farmakoterapiâ v Kardiologii1819-64462225-36532016-01-016448148410.20996/1819-6446-2010-6-4-481-484843EFFICACY OF VARIOUS DRUG FORMS OF LYCOPENE IN PATIENTS WITH DYSLIPIDEMIAP. Ya. Dovgalevsky0V. A. Klochkov1N. E. Chalyk2O. M. Ansimova3I. Petyaev4Saratov Research Institute of CardiologySaratov Research Institute of CardiologySaratov Research Institute of CardiologySaratov Research Institute of CardiologyCambridge Theranostics Ltd., University of CambridgeAim. To find the optimal scheme of lycopene application and to compare clinical efficacy of two lycopene presentations produced on the basis of 1) vegetable oil and 2) milk protein (lactolycopene) in patients with dyslipidemia.Material and methods. At the first step of the study to choice an optimal scheme of pharmacotherapy efficacy of three schemes of lycopene (lactolycopene) application was compared in three groups of patients (n= 27, 25 and 28 respectively) with ischemic heart disease, dyslipidemia and high level of lipid peroxygenation (LPO). At the second step two groups of patients (n=28 and 31) with dyslipidemia received lycopene in the same dose at the same time but in different presentations. Patients of the first group received oil solution of lycopene in capsules, patients of the second group — a powder of lactolycopene dissolved in 100 ml of boiled water. Levels of total cholesterol (TC), high density (HDC) and low density cholesterol (LDC), triglycerides (TG) and LPO activity marker, malondialdehyde (MDA), were studied. The duration of each study step was 8 weeks.Results. Lactolycopene 10 mg QD for the night was as effective as 10 mg TID (30 mg per day) in normalization of the lipid metabolism parameters and malondialdehyde level due to chronopharmacological mechanism. Similar efficacy of the evening lactolycopene reception 10 mg QD and 30 mg QD was due to the saturation of tissues with an antioxidant. Lactolycopene application led to significant reduction in levels of TC (from 247.1±27 to 186.5±12 mg/dl; p<0.001), LDC (from 150.9±17 to 119.3±8 mg/dl; p<0.001), TG (from 165.8±12 to 128±10 mg/dl; p<0.001) and MDA (from 2.67±0.2 to 1.3±0.07 nM/ml; p<0.001) unlike reception of oil solution of lycopene.Conclusion: Lactolycopene has higher effect on lipid metabolism and LPO in comparison with this in lycopene in oil solution presentation. An optimal scheme of lactolycopene reception is 10 mg for the night.https://www.rpcardio.com/jour/article/view/844antioxidantsbioavailabilitydrug presentationdyslipidemia
collection DOAJ
language English
format Article
sources DOAJ
author P. Ya. Dovgalevsky
V. A. Klochkov
N. E. Chalyk
O. M. Ansimova
I. Petyaev
spellingShingle P. Ya. Dovgalevsky
V. A. Klochkov
N. E. Chalyk
O. M. Ansimova
I. Petyaev
EFFICACY OF VARIOUS DRUG FORMS OF LYCOPENE IN PATIENTS WITH DYSLIPIDEMIA
Racionalʹnaâ Farmakoterapiâ v Kardiologii
antioxidants
bioavailability
drug presentation
dyslipidemia
author_facet P. Ya. Dovgalevsky
V. A. Klochkov
N. E. Chalyk
O. M. Ansimova
I. Petyaev
author_sort P. Ya. Dovgalevsky
title EFFICACY OF VARIOUS DRUG FORMS OF LYCOPENE IN PATIENTS WITH DYSLIPIDEMIA
title_short EFFICACY OF VARIOUS DRUG FORMS OF LYCOPENE IN PATIENTS WITH DYSLIPIDEMIA
title_full EFFICACY OF VARIOUS DRUG FORMS OF LYCOPENE IN PATIENTS WITH DYSLIPIDEMIA
title_fullStr EFFICACY OF VARIOUS DRUG FORMS OF LYCOPENE IN PATIENTS WITH DYSLIPIDEMIA
title_full_unstemmed EFFICACY OF VARIOUS DRUG FORMS OF LYCOPENE IN PATIENTS WITH DYSLIPIDEMIA
title_sort efficacy of various drug forms of lycopene in patients with dyslipidemia
publisher Stolichnaya Izdatelskaya Kompaniya
series Racionalʹnaâ Farmakoterapiâ v Kardiologii
issn 1819-6446
2225-3653
publishDate 2016-01-01
description Aim. To find the optimal scheme of lycopene application and to compare clinical efficacy of two lycopene presentations produced on the basis of 1) vegetable oil and 2) milk protein (lactolycopene) in patients with dyslipidemia.Material and methods. At the first step of the study to choice an optimal scheme of pharmacotherapy efficacy of three schemes of lycopene (lactolycopene) application was compared in three groups of patients (n= 27, 25 and 28 respectively) with ischemic heart disease, dyslipidemia and high level of lipid peroxygenation (LPO). At the second step two groups of patients (n=28 and 31) with dyslipidemia received lycopene in the same dose at the same time but in different presentations. Patients of the first group received oil solution of lycopene in capsules, patients of the second group — a powder of lactolycopene dissolved in 100 ml of boiled water. Levels of total cholesterol (TC), high density (HDC) and low density cholesterol (LDC), triglycerides (TG) and LPO activity marker, malondialdehyde (MDA), were studied. The duration of each study step was 8 weeks.Results. Lactolycopene 10 mg QD for the night was as effective as 10 mg TID (30 mg per day) in normalization of the lipid metabolism parameters and malondialdehyde level due to chronopharmacological mechanism. Similar efficacy of the evening lactolycopene reception 10 mg QD and 30 mg QD was due to the saturation of tissues with an antioxidant. Lactolycopene application led to significant reduction in levels of TC (from 247.1±27 to 186.5±12 mg/dl; p<0.001), LDC (from 150.9±17 to 119.3±8 mg/dl; p<0.001), TG (from 165.8±12 to 128±10 mg/dl; p<0.001) and MDA (from 2.67±0.2 to 1.3±0.07 nM/ml; p<0.001) unlike reception of oil solution of lycopene.Conclusion: Lactolycopene has higher effect on lipid metabolism and LPO in comparison with this in lycopene in oil solution presentation. An optimal scheme of lactolycopene reception is 10 mg for the night.
topic antioxidants
bioavailability
drug presentation
dyslipidemia
url https://www.rpcardio.com/jour/article/view/844
work_keys_str_mv AT pyadovgalevsky efficacyofvariousdrugformsoflycopeneinpatientswithdyslipidemia
AT vaklochkov efficacyofvariousdrugformsoflycopeneinpatientswithdyslipidemia
AT nechalyk efficacyofvariousdrugformsoflycopeneinpatientswithdyslipidemia
AT omansimova efficacyofvariousdrugformsoflycopeneinpatientswithdyslipidemia
AT ipetyaev efficacyofvariousdrugformsoflycopeneinpatientswithdyslipidemia
_version_ 1717816818005966848